Pegloticase

Phase 3

Amgen Inc. (AMGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Uncontrolled Gout

View Full Landscape

Drug Information

Target Indication

Uncontrolled Gout

Clinical Trial

NCT07388498

Last updated: 6/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/8/2013

Krystexxa

Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

TarlatamabPhase 3

Small Cell Lung Cancer